Isolation of Fully Vancomycin-Resistant Streptococcus thoraltensis from the Nasal Cavity of a Healthy Young Adult.


Journal

Microbial drug resistance (Larchmont, N.Y.)
ISSN: 1931-8448
Titre abrégé: Microb Drug Resist
Pays: United States
ID NLM: 9508567

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 18 10 2018
medline: 2 8 2019
entrez: 18 10 2018
Statut: ppublish

Résumé

Streptococcus thoraltensis was first isolated from pigs and rabbits. Later, isolation from human oral and nasal cavities and from throat and oropharynx was documented. S. thoraltensis was isolated from patients with periodontitis, tonsillopharyngitis, and chorioamnionitis suggesting a possible pathological role in human infections. All S. thoraltensis isolates of animal and human origins were sensitive to vancomycin. Standard microbiological identification methods, biochemical analysis, and antibiotic susceptibility testing using disk diffusion and E methods were used. Automatic species identification and antibiotic susceptibility testing were carried out using the Vitek 2 compact system. Molecular analysis of vancomycin resistance gene was carried out using a PCR with specific primers for vanA. We report a healthy young female adult, aged 19 years, with history of exposure to pet rabbit who had nasal colonization with S. thoraltensis. Identification of S. thoraltensis was based on traditional microbiological methods (culture, Gram stain, and biochemical tests), and the Vitek 2 compact system with 97% confidence rate. Antibiotic susceptibility testing of the isolate indicated resistance to most antibiotics, including penicillins, cephalosporins, methicillin, and glycopeptides. The minimal inhibitory concentration for vancomycin and teicoplanin was exceptionally high (>256 μg/mL). Molecular analysis indicated the absence of vanA gene in S. thoraltensis. We report for the first time the isolation of a fully vancomycin-resistant S. thoraltensis independent of vanA from a healthy human anterior nasal cavity. The pathological role of this newly identified organism with an exceptionally rare resistance pattern in human infections is yet to be identified.

Sections du résumé

BACKGROUND BACKGROUND
Streptococcus thoraltensis was first isolated from pigs and rabbits. Later, isolation from human oral and nasal cavities and from throat and oropharynx was documented. S. thoraltensis was isolated from patients with periodontitis, tonsillopharyngitis, and chorioamnionitis suggesting a possible pathological role in human infections. All S. thoraltensis isolates of animal and human origins were sensitive to vancomycin.
METHODS METHODS
Standard microbiological identification methods, biochemical analysis, and antibiotic susceptibility testing using disk diffusion and E methods were used. Automatic species identification and antibiotic susceptibility testing were carried out using the Vitek 2 compact system. Molecular analysis of vancomycin resistance gene was carried out using a PCR with specific primers for vanA.
RESULTS RESULTS
We report a healthy young female adult, aged 19 years, with history of exposure to pet rabbit who had nasal colonization with S. thoraltensis. Identification of S. thoraltensis was based on traditional microbiological methods (culture, Gram stain, and biochemical tests), and the Vitek 2 compact system with 97% confidence rate. Antibiotic susceptibility testing of the isolate indicated resistance to most antibiotics, including penicillins, cephalosporins, methicillin, and glycopeptides. The minimal inhibitory concentration for vancomycin and teicoplanin was exceptionally high (>256 μg/mL). Molecular analysis indicated the absence of vanA gene in S. thoraltensis.
CONCLUSION CONCLUSIONS
We report for the first time the isolation of a fully vancomycin-resistant S. thoraltensis independent of vanA from a healthy human anterior nasal cavity. The pathological role of this newly identified organism with an exceptionally rare resistance pattern in human infections is yet to be identified.

Identifiants

pubmed: 30328745
doi: 10.1089/mdr.2018.0092
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
VanA ligase, Bacteria 0
Vancomycin 6Q205EH1VU
Carbon-Oxygen Ligases EC 6.1.-

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

421-426

Auteurs

Mohammad Al-Tamimi (M)

Department of Basic Medical Sciences, Faculty of Medicine, Hashemite University , Zarqa, Jordan .

Nisreen Himsawi (N)

Department of Basic Medical Sciences, Faculty of Medicine, Hashemite University , Zarqa, Jordan .

Jumana Abu-Raideh (J)

Department of Basic Medical Sciences, Faculty of Medicine, Hashemite University , Zarqa, Jordan .

Deaa Abu Jazar (D)

Department of Basic Medical Sciences, Faculty of Medicine, Hashemite University , Zarqa, Jordan .

Hussam Al-Jawaldeh (H)

Department of Basic Medical Sciences, Faculty of Medicine, Hashemite University , Zarqa, Jordan .

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH